Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
Contrary to common myth, women with
pressure that is controlled by medication can take hormone therapy (HT) because
hormone therapy (HT) does not
cause significant elevations in blood pressure. A major medical reason for not
taking hormone therapy (HT) is a personal medical history of breast cancer or uterus cancer. Women with abnormal
vaginal bleeding should have an evaluation prior to embarking on hormone therapy
(HT) to exclude
the presence of cancer of the uterus. Similarly, routine mammograms and breast
examinations are important to exclude the presence of breast cancer.
While hormone therapy (HT) may be used in women with migraines or liver
disease, certain types of hormone therapy (HT) (often
a patch or vaginal form) may be chosen to try to avoid aggravating these
Women should not be taking hormone therapy (HT) to prevent heart
disease, and should initiate hormone therapy (HT) only with caution if they already have been
diagnosed with coronary artery disease (such as past heart attack), as
hormone therapy (HT) may be increase the risk of
Women with a personal history of deep vein thrombosis
clots in the veins) should avoid hormone therapy (HT).
Women with phosopholipid antibodies, including cardiolipin antibiotics
or lupus anticoagulant, should not take HT because of the added risk of
blood clotting and thrombosis.